Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCL-HB01
- Development stage
- Phase 2
- Lead developer
- Vical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
VCL-HB01 is a therapeutic DNA vaccine candidate developed by Vical Incorporated in collaboration with the University of Washington for the treatment of symptomatic genital herpes caused by herpes simplex virus type 2 (HSV-2). The vaccine is a bivalent formulation consisting of two plasmids encoding the HSV-2 antigens glycoprotein D (gD) and the tegument proteins UL46 and UL47. It utilizes Vical's proprietary Vaxfectin® adjuvant, a lipid-based delivery system designed to enhance the immune response, particularly T-cell activity. The program aimed to reduce viral shedding and the frequency of lesion recurrences in seropositive individuals. However, Vical discontinued the development of VCL-HB01 in 2017 after the vaccine failed to meet its primary endpoint of reducing the annualized rate of genital herpes recurrences in a Phase 2 clinical trial.
- Other names
- HSV-2 therapeutic DNA vaccineHSV2 therapeutic DNA vaccineHSV 2 therapeutic DNA vaccineVical HSV-2 vaccine
02
Targets
gD (HSV-2 glycoprotein D)UL46 (Herpes simplex virus type 2 UL46 protein)UL47 (Herpes simplex virus type 2 tegument protein VP13/14)
Beyond the preview
Go deeper on VCL-HB01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCL-HB01.